Did grandma give you heart disease? The new battle against coronary artery disease

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 2, 1998, Pages 34-46

  Superko, H Robert ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Berkeley HeartLab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FIBRIC ACID DERIVATIVE; FOLIC ACID ANTAGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PYRIDOXINE;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION FUNCTION; COST BENEFIT ANALYSIS; DIET; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GEL ELECTROPHORESIS; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; INHERITANCE; PRIORITY JOURNAL; SCREENING TEST; WEIGHT REDUCTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; DIET; FEMALE; HEART DISEASES; HUMANS; LIPIDS; MALE; PEDIGREE; PROGNOSIS; RISK FACTORS;

EID: 0032512066     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00771-1     Document Type: Article

References (96)

1. Superko HR. Beyond LDL-C reduction. Circulation 1996;94:2351-2354.
2. Superko HR. Inherited disorders in the lipoprotein system. A common cause of premature heart disease. In: Julian DG, Wenger NK, eds. Women and Heart Disease. London: Martin Dunitz, 1997:49-67.
3. Droen DM, Fernstrom H, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994;8:121-126.
4. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, Schaefer EJ. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low-density lipoprotein cholesterol. J Lipid Res 1994;35:1965-1975.
5. Superko HR. New aspects of cardiovascular risk factors including small, dense LDL, homocystinemia, and Lp(a). Curr Opin Cardiol 1995;10:347-354.
6. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature CAD. Circulation 1992;85:2025-2033.
7. Goldbourt U, de Faire U, Berg K. Genetic Factors in Coronary Heart Disease. Hingham, MA: Kluwer Academic, 1994.
8. Rissanen AM. Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol 1979;44:60-66.
9. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64:555-559.
10. Superko HR. Small dense LDL. The new CAD risk factor and how it is changing the treatment of CAD. Prev Cardiol 1998;Winter:16-24.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
12. Campeau L, Knatterud GL, Domanski M, Hunninghake DB, White CW, Geller NL, Rosenberg Y, Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
13. Alderman EL, Haskell WL, Fair JM, Superko HR, Maron DJ, Champagne MA, Mackey SF, Williams PT, Krauss RM, Farquhar JW. Beneficial angiographic and clinical response to multifactor modification in the Standard Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-990.
14. Superko HR. Out with the old and in with the new thinking on lipids and heart disease. Curr Opin Cardiol 1997;12:180-187.
15. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low-density lipoprotein particles. J Clin Invest 1993;92:141-146.
16. Superko HR. The atherogenic lipoprotein profile. Sci Med 1997;4:36-45.
17. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-349.
18. Krauss RM, Blanch PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992;3:377-383.
19. Austin MA, Mykkanen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, Pyorala K, Lasako M. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995;92:1770-1778.
20. Superko HR, Krauss RM, Alderman EM. Diabetics have rapid arteriographic coronary disease progression but also arteriographic benefit from risk reduction. (Abstr.) Circulation 1997;96:4289.
21. Nishina PM, Johnson JP, Naggert JK, Krauss RM. Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992;89:708-712.
22. Rotter JI, Bu X, Cantor R, Warden CH, Zia YR, De Meester C, Teryua S, Lockensgard B, Daneshmand S, Brown J, Gray RJ, Krauss RM, Lusus AJ. Multilocus genetic determination of LDL particle size in coronary artery disease families. (Abstr.) Clin Res 1994;42:16A.
23. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis and longevity. Circulation 1966;34:679-697.
24. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921.
25. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888.
26. Gardner CD, Fortmann SP, Krauss RM. Small low-density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-881.
27. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
28. Superko HR, Krauss RM, Miller B. Prediction of LDL subclass pattern from Trig, HDL-C, LDL-C, apoB. Cardiovascular Health Feb 19, 1998.
29. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770.
30. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;ii:62-65.
31. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss R. Intermediate-density lipoproteins and progression of carotid arterial wall intimamedia thickness. Circulation 1997;95:2022-2026.
32. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidology 1995;6:209-214.
33. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM. Predominance of mid-density low-density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study. (Abstr.) Circulation 1994;90:I-460CAD.
34. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-1467.
35. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146-2153.
36. Zambon A, Brown BG, Hokansen JE, Brunzell JD. Hepatic lipase changes predict coronary artery disease regression progression in the Familial Atherosclerosis Treatment Study. (Abstr.) Circulation 1996;94:I-539CAD.
37. Superko HR, Krauss RM, and the SCRIP investigators. Arteriographic benefit of multifactorial risk reduction in patients with LDL-C <125 mg/dL is seen in LDL pattern B but not pattern A. 4th International Symposium on Multiple Risk Factors in Cardiovascular Disease. Washington, DC, April 1997. (Abstr.)
38. Scanu AM, Gless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-1715.
39. Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb 1994;14:1609-1616.
40. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM, Patsch W, and the ARIC study group. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. Arterioscler Thromb 1993;13:1139-1158.
41. Scanu A. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA 1992;267:3326-3329.
42. Grainger DJ, Metcalfe JC. Transforming growth factor-beta: the key to understanding lipoprotein(a)? Curr Opin Lipidol 1995;6:81-85.
43. Bostrom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA 1996;276:544-548.
44. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995;91:948-950.
45. Sandkamp M, Funke H, Schelte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23.
46. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765.
47. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994;14:1730-1736.
48. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994;271:999-1003.
49. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994;90:1688-1695.
50. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lesperance J, Campeau L. Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol 1993;72:1215-1219.
51. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
52. Maher VMG, Brown BG, Marcovina S, Hilger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-1774.
53. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Hishikawa H, Takatsu F, Kata H, Kutsumi Y, Yamada N, Noma A, Yamaguchi H, and the L-ART group. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994;73:1037-1040.
54. Virchow R. Von Gesammelte Abhandlungen zur Wissenschaftlichen. Berlin: Medicia, Müller, 1856:485.
55. Mudd SH, Levy HL. Disorders of transsulfuration. In: Stanbury JB, Wingarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1983:522-559.
56. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
57. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
58. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830.
59. Malinow MR. Hyperhomocystinemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81:2004-2006.
60. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:460-464.
61. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993;13:1327-1333.
62. Stamler JS, Osborne JA, Jarake O, Rabbani LE, Mullins M, Singel D, Loscolzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
63. Tawakol A, Omland O, Gerhard M, Wu JT, Creager MA. Hyperhomocystinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121.
64. Stampfer MJ, Mallnow R, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
65. Malinow MR, Nieto J, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-1114.
66. Nygard O, Nordrehaug E, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
67. Superko HR, Krauss RM. Small LDL, elevated triglycerides and increased homocysteine response to a methionine load identify a high-risk restenosis group. Xth International Symposium on Atherosclerosis. Montreal, October 1994.
68. Superko HR. High HDL-C, not protective in the presence of homocystinemia. Am J Cardiol 1997;79:705-706.
69. Dreon DM, Fernstrom HA, Williams PT, Krauss RM. LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women. Arterioscler Thromb Vasc Biol 1997;17:707-714.
70. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1-11.
71. Dachet C, Cavallero E, Martin C, Girardot G, Jacotot B. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis 1995;113:1-9.
72. Superko HR, Krauss RM. Reduction of small, dense LDL by gemfibrozil in LDL subclass pattern B. (Abstr.) Circulation 1995;92:I-250CAD.
73. Superko HR, and the KOS investigators. Effect of nicotinic acid on LDL subclass patterns. (Abstr.) Circulation 1994;90:I-504CAD.
74. Superko HR, Williams PT, Alderman EL, and the Stanford Coronary Risk Intervention Project Investigators. Differential lipoprotein effects of bile acid binding resin in LDL subclass pattern A versus B. (Abstr.) Circulation 1992;86:I-144CAD.
75. Superko HR, Krauss RM, DiRicco C. Effect of HMG-CoA reductase inhibitor (fluvastatin) on LDL peak particle diameter. Am J Cardiol 1997;80:78-81.
76. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995;114:223-234.
77. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14:1569-1575.
78. Williams PT, Krauss RM, Vranizan KM, Wood PD. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation 1990;81:1293-1304.
79. Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins during weight loss by dieting versus exercise in overweight men. N Engl J Med 1988;319:1173-1179.
80. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313-1319.
81. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-276.
82. Brewer HB Jr. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM, ed. Lipoprotein(a). New York: Academic Press, 1990:211-220.
83. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293-301.
84. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetyl cysteine. Lancet 1991;337:203-204.
85. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-281.
86. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Jkena T, Weale V, Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-1593.
87. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-221.
88. 6, pyridoxal phosphate, and folate. Am J Cardiol 1995;75:1107-1111.
89. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocystinemia in an elderly population. JAMA 1993;270:2693-2698.
90. Blankenhorn DH, Malinow MR, Mack WJ. Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Artery Dis 1991;2:357-360.
91. Frick MH, Elo O, Haapa K, Heinonen P, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila FA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
92. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37-45.
93. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH. Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the cholesterol-lowering atherosclerosis study (CLAS). (Abstr.) Circulation 1993;88:I-363CAD.
94. Superko HR. Cost-effective treatment of coronary artery disease. The new imperative. Clin Cardiol 1996;19:650-655.
95. Superko HR. Failure of cholesterol treatment in CAD patients. A cost-effective solution. (Editorial.) Am J Cardiol 1995;75:277.
96. Dunn PL, Superko HR, Meese RB, Williams P. Cardiovascular risk reduction is cost effective in the real world. (Abstr.) Circulation 1997;96:I-67.